For instance, in triple-negative breast cancer, the small molecule inhibitor WX2-43 blocks KLF4 methylation by inhibiting the Protein Arginine Methyltransferase 5 (PRMT5) -KLF4 interaction, showing significant antitumor efficacy (162). Here, KLF4 is linked to triple-negative breast carcinoma.